Introduction
Bone formation in development and regeneration requires proliferative expansion of preosteoblasts and their subsequent differentiation. These two processes rely on the function and temporal coordination of multiple transcriptional regulators. In particular, Runx2 and Sp7/Osx are essential to osteogenesis as deletion of either impairs osteoblast differentiation and eliminates bone formation (Komori et al., 1997; Nakashima et al., 2002) . Runx2 regulates the expression of Sp7/Osx as well as the bone matrix proteins Ocn, Bsp, and Opn (Komori, 2005) . Runx2 also promotes the expression of Atf4, a regulator of terminal differentiation in osteoblasts (Yang et al., 2004) .
The function of these transcription factors is augmented by Satb2 (Special AT-rich sequence binding protein 2), a protein that binds to nuclear matrix-attachment regions (MARs). It is thought that Satb2 organizes chromatin looping at MARs such that the expression of celltype specific differentiation genes may be enhanced (Britanova et al., 2005) . In mice, loss of Satb2 results in skeletal hypoplasia and reduced expression of osteogenic genes including Ocn and Bsp (Dobreva et al., 2006) . In contrast, Satb2 over-expression was found to promote bone formation and increase Ocn and Bsp expression (Gong et al., 2014; Zhang et al., 2011) . These results are consistent with skeletal malformations in humans with SATB2-associated syndrome (SAS), which include bowing tibias, low bone mineral density with high fracture rate, osteoporosis, cleft palate, micrognathia, and maxillary hypoplasia (Boone et al., 2016; Leoyklang et al., 2007; Zarate and Fish, 2017; Zarate et al., 2018a; Zarate et al., 2018b) .
One role of Runx2 in pre-osteoblasts is to down-regulate the miR cluster 23a/27a/24-2. These miRs target the 3' UTR of Satb2, and thus Runx2 alleviates the repression of Satb2 (Hassan et al., 2010) . These and other data have placed Satb2 downstream of Runx2 in the osteogenic differentiation program, with mutations in Satb2 largely thought to impair the expression key genes involved in osteoblast maturation (Dobreva et al., 2006; Gong et al., 2014; Zhang et al., 2011) . Although the majority of investigations into Satb2 function in osteogenesis have focused on its role in gene regulation, loss of Satb2 has also been reported to cause apoptosis in neural crest progenitors of the jaw (Britanova et al., 2006; Fish et al., 2011) .
To further explore molecular and cellular mechanisms underlying Satb2-mediated defects in osteogenesis, we used the CRISPR/Cas9 system to generate mutations in the Satb2 locus in MC3T3-E1 cells, which are clonal pre-osteoblasts that have been widely used as a model of osteoblast differentiation (Xiao et al., 1997) . Several modified colonies with different combinations of Satb2 alleles producing a range of Satb2 expression levels were selected for experimental analysis. Consistent with previous reports, we observe altered osteogenic gene expression in Satb2 mutants. However, we also find that reduction in Satb2 expression, even that of true heterozygotes, results in reduced pre-osteoblast proliferation. Further, mutations in Satb2 cause nuclear aberrations including nuclear blebbing and donut-shaped nuclei.
Our data point to a novel role for Satb2 in mediating pre-osteoblast proliferation, indicating that Satb2 is involved in both proliferative expansion of pre-osteoblasts and their subsequent differentiation. Previous studies failing to observe proliferation defects in Satb2 mutants may reflect buffering of this process in some genetic backgrounds. The potential role of genetic background in regulating susceptibility to Satb2-mediated proliferation defects may help explain variation in penetrance and severity of skeletal defects in SAS patients. Participation in both proliferation and differentiation processes makes Satb2 an interesting target for bone regeneration and osteoporosis therapies (Guo et al., 2016; Zhang et al., 2011) . Finally, our observation that mutations in Satb2 both reduce proliferation and cause nuclear aberrations has implications for understanding its dichotomous potential for both tumor suppression and oncogenesis (Chen and Costa, 2018) .
Materials and Methods

Cell lines
Mouse osteoblast precursor cells (MC3T3-E1 Subclone 4) obtained from ATCC were grown in aMEM supplemented with 10% FBS and Penicillin/Streptomycin. Passage numbers higher than 20 were discarded.
Generation of mutant lines using CRISPR/Cas9
To generate indel mutations near the start codon of Satb2 (Fig. 1A) , we used a previously validated guide RNA, Satb2-272, ATCGGAGCAGCATGGAGCGG (Shinmyo et al., 2016) . The guide RNA was cloned into pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene plasmid # 62988), as previously described (Ran et al., 2013) . Cells were transfected using the NEON transformation system (Invitrogen) using one 1200V pulse and a 30 ms pulse width and otherwise following the manufacturer's protocol. 48-hours after electroporation, 3 µg/mL Puromycin was added to the cells for 24 hours. Surviving cells were diluted to 2.5 cells/ml and seeded into 96-well plates at 0.5 cells per well to obtain single cell colonies. Single colonies were grown to confluency and then expanded.
Analysis of mutant cell lines
DNA was extracted from single cell colonies using the ZR Duet DNA/RNA Miniprep Kit (Zymo). A 708 bp PCR product around the editing site of Satb2-272 was amplified using primers Satb2-seq-F ACTGGCCTGATCGTCTATCA and Satb2-seq-R GCCAGATCCTAGGTCTCTGT. PCR fragments were cloned into TOPO pCR4 (Invitrogen) and sequenced with M13 F+R primers using Sanger sequencing to determine the exact sequence of each allele.
Differentiation assay
An overview of the differentiation assay is shown in Figure 6A . Cells were plated in a 12-well plate at 5 x 10 4 cells per well. After 3 days, differentiation was induced (=T0) with Dulbecco's modified Eagle Medium supplemented with 10% FBS, Penicillin/Streptomycin, 50 µg/ml betaglycerophosphate, and 200 µM ascorbic acid. The media was changed every 2-3 days over the differentiation period (0-28 days). Mineralization was detected with 1% (w/v) Alizarin S pH 4.2 for 1 h and imaged on an Epson Perfection 4990 Photo scanner and an Olympus BX41 microscope.
Immunohistochemistry
Cells were fixed in 4%PFA/PBS for 15 minutes, permeabilized with 0.1% Triton-X-100/PBS and then blocked in 5% FBS supplemented with 0.1% BSA for 1 h. For BrdU, cells were treated with an additional incubation in 2N HCl for 1 h at room temperature after the permeabilization. Primary antibodies were incubated overnight at 4°C in blocking solution at the following concentrations: mouse anti-Satb2 (SATBA4B10, SantaCruz) 1:300; mouse anti-alpha Tubulin (DM1A) 1:500; mouse anti-Lamin B1 (B-10, SantaCruz) 1:100; rabbit anti-Lamin A/C (Cell Signaling Technology) 1:100; rabbit anti-BrdU (Abcam) 1:50. Cells were imaged on a Nikon AR-1, a Leica Sp8, or a Zeiss Axiovert 200M microscope. Images were processed using the Fiji distribution of ImageJ and Adobe Photoshop CC 2018 (Schindelin et al., 2012) .
Imaging flow cytometry
Cells for the flow analysis were plated at 4 x 10 5 four days before the experiment. After trypsinizing, cells were resuspended in media and counted using a hemocytometer. Cells were spun down, resuspended in PBS to 1 x 10 6 , and incubated for 15 min at room temperature in the dark in 1x Annexin Binding Buffer (Invitrogen) supplemented with 2 µl Annexin V, Alexa Flour 488 conjugate (Invitrogen) and 0.5 µg/ml propidium iodide (Alfa Aesar). After a final centrifugation step, cells were resuspended in 100 µl 1x Annexin Binding Buffer and then analyzed immediately on an Amnis imaging flow cytometer with a 20x objective. Both Annexin V A488 and PI were excited using the 488 laser. Brightfield (channel 01 and 09, 435-480 nm and 570-595 respectively), Annexin V A488 (channel 02, 480-560 nm) and PI (channel 04, 595-642 nm) were measured and 10000 single cell events (see gating below) were counted and all events collected. Color compensation was achieved using single-stained samples that contained cells in which apoptosis was induced by incubating cells for 24-48h with 5 µM camptothecin. Focused cells were gated using the gradient root mean square of the bright field image, and bright field area and aspect ratio were used to gate single cells. Using fluorescence intensity of channel 02 (Annexin V A488) and channel 04 (PI), cells were divided into double negative (live) cells, Annexin V-positive cells (early apoptotic) and double positive cells (late apoptotic and necroptotic).
qPCR
RNA was collected with the illustra triplePrep kit (GE healthcare) or TRIzol (Invitrogen). RNA was DNase-treated with the TURBO DNA-Free kit (Invitrogen) and quantified using a Qubit 3 Fluorometer (Invitrogen). cDNA was generated with 400ng of RNA with iScript RT Supermix for RT-qPCR (BioRad). GAPDH and Satb2 primers were from (Gong et al., 2016) GCCGGAGTCTGTTCACTACC). Fold change was calculated using the delta-delta C(t) method (Livak and Schmittgen, 2001) .
Single Cell qPCR
Cells were trypsinized and at T14 or later also treated with collagenase type 1 (Worthington) for 15-30 min at 37°C. Cells were loaded onto a C1 Single-Cell Preamp integrated fluidic circuit (IFC) with 17-25 μm capturing well size. Primers for pre-amplification were obtained from Fluidigm (Delta Gene Assays, see Supplementary Table 1) . After single-cell capturing, the inlets of the IFC were microscopically checked for the presence of single cells. Empty inlets or inlets with two or more cells were recorded and excluded from the qPCR analysis. Lysis, reverse transcription and preamplification was performed according to protocol. Single cell qPCR was performed using the Fluidigm BioMark system on 96.96 Dynamic Array IFCs for Gene Expression using Delta Gene Assays and Sso Fast EvaGreen Supermix with Low ROX (BioRad). Single cell qPCR was performed using the Fluidigm BioMark system on 96.96 Dynamic Array IFCs for Gene Expression using Delta Gene Assays and 2X SsoFast EvaGreen Supermix with low ROX (Bio-Rad). For data-processing, the Fluidigm Real-Time PCR Analysis Software v4.5.2 was used to eliminate failed assays. The default quality threshold cutoff (0.65) was used to identify potential artifacts. The baseline correction was to linear, and the Ct threshold detection method was set to Auto (Detectors). The Fluidigm Singular Analysis Toolset v3.6.2 was used in R to analyze single cell gene expression. The statistical computing software R was used to identify patterns in gene expression.
Results
Satb2 mutant lines
We selected several CRISPR/Cas9-modified cell lines with different types of mutations for analysis. Our selected colonies include two heterozygous lines and two homozygous mutant lines (Fig. 1) . Of the heterozygous lines, one is a true heterozygote with one WT allele and one loss of function allele (colony 19), while the other heterozygote has an allele missing a single amino acid at the N-terminal end (with predicted WT function) and an allele with a N-terminal 6bp deletion that includes the ATG (colony 9). Of the two homozygous mutant lines, one is a complete loss of function mutant with two alleles carrying frameshift deletions (colony 8). The other has one allele with a 7bp deletion and one allele with a 143bp insertion, both removing the ATG (colony 4).
Satb2 mRNA and protein levels were evaluated in each of these lines by qPCR and Western blot, respectively. Using two sets of primers (A and C in Fig.1A ), we find that no fulllength mRNA is produced for any allele containing a mutation in the start codon (SupFig. 1A). Using primers directed against the C-terminal end of the gene, we find Satb2 mRNA is produced in all our cell lines. However, some of this mRNA (especially that of colony 8) is predicted to form non-functional (frame-shifted) protein or not be translated at all. Western blot confirmed colony 8 is a loss of function mutant (SupFig. 1B). Similarly, colony 19 produces roughly half the amount of Satb2 protein relative to WT, as expected for a true heterozygote. Interestingly, we found that the short N-terminal deletions found in colonies 9 and 4 produce a protein. Although the start codon is deleted in both affected alleles, another ATG exists 120bp downstream. Our data are consistent with this allele producing a Satb2 protein missing the first 40 amino acids. These 40 amino acids are not part of any previously described functional domains (Fig. 1A) .
Immunostaining using an antibody targeted against the C-terminal end of Satb2 provides results consistent with our Western blot analyses (Fig. 2) . Importantly, the immunostaining data confirm the production of protein lacking the N-terminal 40 amino acids (see C4 in Fig. 2) . Also of note is that in colony 9, which produces 2 Satb2 proteins of different sizes, the shorter protein appears to be preferentially produced (SupFig. 1B). This preference for producing the shorter protein has been observed in 4 separate Western blots.
Satb2 and the cell cycle
When assessing Satb2 levels, we noticed that in all cell lines, Satb2 exhibits population variation (Fig. 2) . In interphase cells, Satb2 ranges from intense to weak, although always associated with euchromatin. Satb2 is present in early mitosis, however it is no longer associated with chromatin, and is absent by late mitosis ( Fig. 2A and 3A) . As part of our experiments to investigate variation in osteogenic gene expression (described below), we performed single cell gene expression analyses. Interestingly, we found that in WT cells, Satb2 expression levels cluster among cell cycle regulators rather than with genes associated with osteogenic differentiation (SupFig. 2). Notably, the relative expression of a sub-set of cell cycle genes associated with late G1 and S phases separated the cells into two main clusters (SupFig. 2). In particular, the genes Cdc25a (G1-S), Cdc6 (S), Cdk2 (G1-S), and Cdk1 (S-M), along with Satb2, were highly expressed in one cluster relative to the other (see rectangle, SupFig. 2). In contrast, expression of genes associated with G1 such as Cdcn1, Cdcn2, Cdk4, and Cdk6, was more widely distributed among cells. These data suggest that Satb2 is cell cycle regulated and/or regulates cell cycle genes.
To further investigate Satb2 variation during the cell cycle, we evaluated Satb2 levels in cells that had been treated with BrdU for 2 hours. We binned cells into 3 classes of Satb2 levels. Low to no Satb2 protein is observed in cells in anaphase through early G1 (see Fig. 2 and 3) . BrdU positive cells, indicating cells in S and G2 have high levels of Satb2, however, high Satb2 levels are also observed in BrdU negative cells (Fig. 3) . Taken together, these data suggest that Satb2 is most active from late G1 to late G2.
Mutations in Satb2 reduce pre-osteoblast proliferation
Previous work has reported a role for Satb2 in regulating osteogenic differentiation, but not found a role in osteoblast proliferation (Dobreva et al., 2006) . We find that mutations in one or more Satb2 alleles result in reduced proliferative capacity of pre-osteoblasts (Fig. 4) . All of the mutant cell lines proliferate more slowly than WT (Fig. 4A) . Notably, colony 4, which expresses only Satb2 protein with the 40aa N-terminal deletion, proliferates even more slowly than all of the other lines, including colony 8, which lacks all Satb2 protein. Additionally, Satb2 mutant cells have a greater than 50% reduction in mitotic cells compared to WT cell lines ( Table  1) .
Decreased proliferation may be also be caused by increased apoptosis. We observed apoptotic cells in our immunostaining assays, but quantification of fixed cells did not indicate a significant increase in numbers ( Table 1) . This may be due to loss of cells during fixation and staining and/or lack of appropriate markers. Therefore, we turned to imaging flow cytometry to quantify dead and dying cells using Annexin V to identify early apoptotic and propidium iodide to identify late apoptotic cells. There is some variation in early apoptotic cell numbers, but very little difference in late apoptotic cell numbers (Fig. 4B,C) . We observe minor variation in these percentages between experiments, but the overall pattern of only subtle increases in apoptosis in our mutant cell lines is consistent. Notably, our loss of function mutant (colony 8) has similar numbers of apoptotic cells as WT (and colony 20), yet still proliferates much more slowly. Taken together with our quantifications on fixed cells, these data indicate that mutations in Satb2 mildly increase apoptosis, but that apoptosis is not sufficient to explain reductions in proliferation.
Mutations in Satb2 generate nuclear aberrations
In our immunostaining assays to detect Satb2 levels, we noticed a number of nuclear aberrations in the mutant cell lines. We defined 4 types of nuclear aberration (Fig. 5) : chromatin bridges (Fig. 5A,B) , large nuclei ( Fig. 5C) , nuclear blebbing or chromatin herniation (Fig. 5D-F) , and donut-shaped nuclei (Fig. 5E,F) . We quantified the abundance of these aberrations in fixed cells ( Table 1 ). All 4 of these aberrations appear more frequently in all of our mutant cell lines relative to WT, suggesting that the aberrations are specific to mutations in Satb2. However, to address the possibility that these aberrations are a consequence of CRISPR/Cas9 treatment, we also quantified cells from colony 20, a line that was subjected to our CRISPR/Cas9 protocol but was genotyped as WT after selection.
In both WT and colony 20 cells, the presence of nuclear aberrations was rare, and always more subtle than those observed in the mutant cell lines. For example, chromatin bridges, which was the most common aberrant phenotype seen in WT cells, are typically present as very thin string-like strands between nuclei (see Fig. 2B ). In contrast, chromatin bridges in the mutant cell lines were often thick as shown in Figure 5B , where Lamin B immunostaining shows folds in DNA within the bridge. Similar folds in DNA can be observed in Figure 5F . Finally, while WT cells exhibit the occasional small nuclear bleb, we only observe the catastrophic blebbing shown in Figure 5E in the mutant cell lines. Large panel overviews of all 6 cell lines from which quantifications were made are available on Mendeley (http://dx.doi.org/10.17632/6yfs85wyy6.1).
Mutations in Satb2 reduce osteogenic differentiation
To investigate how Satb2 mutations in our cell lines affect osteogenic differentiation, we performed an in vitro differentiation assay (Fig. 6) . Differentiation was evaluated by histology (alizarin red) and gene expression (qPCR). By both measures, all of our mutant cell lines, even colony 19, a true heterozygote, exhibit incomplete differentiation relative to WT cells (Fig. 6) . We do observe mineralization, as reflected by alizarin red staining, in all of our colonies. However, none of the colonies form as many nodules of punctate staining as observed in WT cells (Fig. 6B) . Additionally, the expression of bone matrix genes is much lower in all Satb2 mutant cell lines (Fig. 6C) .
As reported above, our mutant cell lines have proliferation defects. Therefore, we tested whether differentiation potential was affected by cell density at the onset of differentiation. We plated cells at 3 different densities prior to differentiation, and also extended our differentiation protocol by an additional week (28 vs. 21 days). Increasing cell number at the onset of differentiation appears to improve osteogenic output as determined by the presence of mineralized nodules (Fig. 3B) . Additionally, extending the differentiation time leads to increased expression of bone matrix proteins (Fig. 3C) . Interestingly, colony 8, the loss of function line, differentiates better than colonies 9 and 19, two heterozygous lines. These data suggest that proliferation defects reducing cell density at the onset of differentiation contribute to reduced osteogenesis in cells with Satb2 mutations.
Satb2 mutations increase gene expression variance
We used single cell gene expression analyses to evaluate how mutations in Satb2 affect osteogenic gene expression. Expression was quantified for 93 genes including 66 related to osteogenesis, 18 related to cell cycle progression, and 7 related to apoptosis (Supplementary Table 1 ). Down-regulation of Satb2 alters the expression profile of differentiating (T14) osteoblasts (Fig. 7 and SupFig. 3) . Single cell expression profiles can be visualized using tSNE plots (Fig. 7A,B) which represent all the variation in the dataset and PCA plots (Fig. 7C,D) which represent 46% and 28% of the variation, respectively. As differentiation proceeds, gene expression becomes increasing distinct between WT and mutant cells. At T0, there is no significant difference between the means or variance the two populations, however by T14, gene expression shows more variance between individual mutant cells than is observed in WT cells (T0, F=1.11, n.s; T14, F=3.19, p=0.01).
The increased variation of gene expression patterns in mutant cells can also be observed by evaluating the number of genes that correlate with Satb2 (SupFig. 3). At T14, the expression of 16 genes positively correlates with Satb2 in WT cells (correlation coefficient of 0.5 and above). In contrast, only 4 genes show correlated expression with Satb2 in T14 mutant cells. No genes in either cell population negatively correlate with Satb2. These data suggest that large-scale alterations to gene expression occur when Satb2 is down-regulated, and that Satb2 mutations lead to increased population variation in osteoblast gene expression.
Discussion
Cell biological mechanism of osteogenic defect
Although it is generally accepted that loss of Satb2 causes bone hypoplasia and low bone mineral density, there is some discrepancy among the reported molecular and cellular mechanisms mediating these phenotypes. In a study focusing on the developing jaw, loss of Satb2 was associated with progenitor cell death, and more specific effects of Satb2 on osteogenic differentiation (in the facial or axial skeleton) were not reported (Britanova et al., 2006) . That study also found that Satb2 +/-heterozygous mice have phenotypes of the craniofacial skeleton that are intermediate between WT and mutant. In a separate study, loss of Satb2 was associated with deficiencies in osteogenic gene expression (Dobreva et al., 2006) . Notably, Dobreva and colleagues (2006) reported that Satb2 +/-mice were phenotypically normal and used them as controls to evaluate gene expression defects in Satb2 -/-mice. In addition to not finding evidence of apoptosis (even in homozygous mutants), Dobreva and colleagues (2006) also report that proliferation of osteoblasts was not affected, although these data were not shown. In general, the craniofacial phenotype shown by Dobreva and colleagues (2006) appears less severe than that shown by Britanova and colleagues (2006) . Here, we find that mutations in Satb2 cause both proliferation and differentiation defects. We also find a dosage effect, where loss of even a single allele of Satb2 causes defects in osteogenesis. Thus, we hypothesize that Satb2 has two cell biological roles in osteogenesis: 1) regulation of preosteoblast proliferation and 2) subsequent osteoblast differentiation (Fig. 8) .
The different results reported in the previous studies described above may be related to differences in genetic background (although the background used in the Dobreva study was not specified). Our work, conducted in the C57BL/6 background (which is the same background used by Britanova and colleagues), indicates that Satb2 mutations increase apoptosis (although not to the extent they observed) in pre-osteoblasts. Additionally, we show that increasing cell density at the onset of proliferation increases differentiation potential. Taken together, these data indicate that proliferation defects in osteogenic progenitors contribute to deficits in bone mineral production, particularly in the C57BL/6 background. Disruption to osteogenic gene expression has been reported in all loss of Satb2 studies, suggesting it is a more penetrant phenotype. If the C57BL/6 background is susceptible to both proliferation and differentiation defects, it would also explain why the jaw phenotype reported by Britanova and colleagues (2006) is more severe. Further, this data raises the interesting possibility for modifiers with the potential to buffer the proliferation defects to be discovered.
Molecular mechanism of osteogenic defect
MAR-binding proteins have at least two distinct molecular roles, transcriptional regulation and DNA replication (Ottaviani et al., 2008b) . MAR-binding proteins regulate transcription by defining the borders of chromatin loops anchored in the nuclear matrix. The anchoring sites form discrete territories of genome organization that serve as transcription hubs, where transcription factors, histone modifying enzymes, and other proteins aggregate to promote gene expression (Cai et al., 2003; Gyorgy et al., 2008; Kirillov et al., 1996; Ottaviani et al., 2008b) . Mutations reducing MAR-binding proteins may limit their ability to properly modify chromatin and/or participate in protein-protein interactions mediating gene transcription thus disrupting the coordinated regulation of cell-type specific genes. For example, in Satb1 mutant mice, gene expression is dysregulated during differentiation of thymocytes and T cells (Alvarez et al., 2000) . Similarly, we observe a significant shift in gene expression and increased variation in gene expression in Satb2 mutant cells. We do not observed increased variance in gene expression in proliferating osteoblasts (T0), but this may be an artifact of the genes used in our single-cell analysis, which are heavily biased towards osteogenic differentiation genes.
However, our finding that proliferation is affected in pre-osteoblasts indicates an additional role for Satb2. Satb2 may also mediate this effect through regulation of transcription of genes important for cell cycle progression. Notably, in a different study in MC3T3-E1 cells where Satb2 was over-expressed, genes associated with cell cycle and proliferation were more upregulated than genes associated with differentiation (Kim et al., 2012) . However, the possibility that Satb2 is more directly involved in DNA replication by binding at MARs remains open, especially as Satb2 is highly expressed from late G1 through G2. If Satb2 is required for DNA replication (either directly through binding at MARs or indirectly through gene regulation), its reduction may cause replication stress, which is associated with DNA damage (Zeman and Cimprich, 2014) . Further investigation into Satb2 involvement in DNA replication could elucidate mechanisms underlying DNA damage observed in Satb2 mutants.
N-terminal domain of Satb2
Several genetic modifications of the SATB2 locus, including deletions, point mutations, duplications, chromosomal translocations, and frameshift and splice site mutations have been implicated in causing SAS (Zarate and Fish, 2017) . Most of these mutations have been hypothesized to mediate disease phenotypes through haploinsufficiency of SATB2. However, few mutations have been functionally tested. In the case of one nonsense mutation, the mutant SATB2 mRNA produces a truncated protein retaining the SATB2 dimerization domain, and lacking the DNA-binding motifs, thus suggesting a dominant negative effect (Leoyklang et al., 2007; Leoyklang et al., 2013) . Some SATB2 activity remains in cells expressing this truncated protein, however, it remains unclear how these levels compare to SATB2 mutations resulting in loss of function. More generally, it is still not well understood how heterozygous loss of function mutations affect SATB2 mRNA and protein levels.
Here we show that mutations in Satb2 result in decreased mRNA and protein levels. Additionally, several observations from our work suggest that mutations may generate proteins with dominant negative effects. First, colony 4 (generating only protein with the N-terminal deletion) proliferates more slowly than colony 8 (complete loss of function). Colony 8 appears to have fewer nuclear aberrations than either colony carrying the N-terminal deletion. Finally, colony 8 differentiates better than the colonies carrying the N-terminal deletion. We used the Phyre 2 software to predict the effect of this deletion on Satb2 structure (Kelley et al., 2015) . Although we did not see any obvious alterations to Satb2 protein folding, we did find that the Nterminal domain is highly disordered (SupFig. 4). Disorder domains are important for protein dissociation (Umezawa et al., 2016) . Chromatin architecture is dynamic and genomic anchors need to be altered throughout the cell cycle to adapt to changing genomic function (Heng et al., 2004; Ottaviani et al., 2008a) . Additionally, chromatin remodeling complexes dissociate from chromatin during mitosis (Ma et al., 2015) . Mutations in the Satb2 N-terminal region may therefore hinder its ability to dissociate from chromatin, disrupting its function and/or contribute to DNA damage.
Variation in disease phenotypes
Individuals with SAS exhibit a broad spectrum of skeletal abnormalities including tibial bowing, osteomalacia, osteopenia or osteoporosis, and they have a high risk for fractures (Zarate et al., 2018b) . The incidence and severity of these skeletal anomalies varies among SAS patients, with some individuals having little to no skeletal problems (Zarate et al., 2018a) . Age at presentation also reflects variability of severity with skeletal morbidity reported as early as infancy. Current available data suggests that for those individuals that have undergone dedicated evaluation for bone density, it is common to have lower age/gender adjusted BMD scores regardless of the type of genetic modification in SATB2. Overall, the current data from SAS patients is consistent with variation in penetrance of skeletal anomalies that is not associated with mutation type. We hypothesize that genetic background underlies these differences, with more severe phenotypes occurring in individuals that are more susceptible to pre-osteoblast proliferation defects.
Anti-resorptive drugs (e.g. bisphosphonates) which increase bone density and strength by inhibiting osteoclast activity, have been the main therapeutic option for individuals with childhood osteopenia in SAS (Zarate et al., 2018b) . The results presented here showing a role for Satb2 in pre-osteoblast proliferation suggest that the low BMD in SAS may be a consequence of a decline in the number and vitality of osteoblasts. Therefore, drugs that directly target osteoblasts such as teriparatide, an anabolic agent that increases osteoblast formation and activates bone-lining cells (quiescent osteoblasts) to form new bone, could provide a biologically sound alternative treatment for osteopenia in SAS.
Implications for cancer
We observed several types of nuclear aberrations, including nuclear blebbing and chromatin herniation, that are also characteristic of cancer cells. A previous study in MC3T3-E1 cells found that Satb2 levels increase in response to oxidative stress. When Satb2 was reduced via siRNA in cells under oxidative stress, apoptosis increased (Wei et al., 2012) . Similarly, Satb1 was recently found to participate in DNA repair associated with oxidative damage (Kaur et al., 2016) . Reductions in Satb2 have also been reported in cancers associated with deficiencies in DNA mismatch repair proteins (Ma et al., 2018) . Together, these data suggest that downregulation of Satb2 may be involved in cancer through compromised DNA repair mechanisms. Paradoxically, over-expression of Satb2 is also associated with cancer in different cell types (Chen and Costa, 2018; Ma et al., 2018) . Our finding that Satb2 is involved with proliferation and DNA damage may explain this dichotomy. Cell-type specific gene regulation may impact how alterations to Satb2 disrupt normal cell biology in cancer progression.
Conclusion
Previous work has described Satb2 is a high-order transcription factor regulating genes required for osteogenic differentiation. Our data suggest that, in addition to its role in differentiation, Satb2 regulates progenitor proliferation. Satb2 may promote pre-osteoblast proliferation through regulation of the expression of genes associated with cell cycle progression and/or it may have a role during DNA replication through its association with MARs. The involvement of Satb2 in separate molecular processes during osteogenesis, one of which may be buffered in certain genetic backgrounds, may help explain variation in disease phenotypes (Merkuri and Fish, 2019) . We have also found that mutations in Satb2 cause chromatin defects. Further investigation of the mechanism underlying these defects has potential impacts on both skeletal defects and cancer. Table 1 
Contributions
